Abstract
Empagliflozin is the only treatment indicated for adult patients with symptomatic chronic heart failure (CHF), regardless of left ventricular ejection fraction (LVEF). The efficacy and safety of empagliflozin, added to optimized standard of care (SoC) therapy, have been demonstrated in two randomized, double-blinded clinical trials: EMPEROR-Reduced in adult patients with symptomatic CHF with reduced LVEF, and EMPEROR-Preserved with LVEF>40%. The aim of this study is to evaluate the direct health costs associated to CHF patients after the introduction of empagliflozin in Spain.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
